Apollomics Share Price
NASDAQ: APLM | HealthcareApollomics Stock Performance
Apollomics Share Price Chart
Apollomics Annual Profit & Loss
All figures in USD
Apollomics Balance Sheet
All figures in USD Million
Apollomics Cash Flow
All figures in USD Million
Corporate Actions
About Apollomics
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. Company has three new immuno-oncology product candidates: APL-501, APL-502 and APL-801 include mono-specific and bi-specific antibodies to fight against cancer.
Apollomics Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Nov 2026 | $20.97 | $16.51 | -19.82% |
Oct 2026 | $21.75 | $20.59 | -14.28% |
Sep 2026 | $27.50 | $24.02 | -5.73% |
Aug 2026 | $17.74 | $25.48 | +45.77% |
Jul 2026 | $19.51 | $17.48 | -15.60% |
Jun 2026 | $14.66 | $20.71 | +42.83% |
May 2026 | $16.30 | $14.50 | +8.90% |
Apr 2026 | $15.06 | $13.31 | -24.30% |
Mar 2026 | $17.59 | $17.59 | -12.62% |
Feb 2026 | $19.13 | $20.13 | +3.12% |
Jan 2026 | $20.20 | $19.52 | +4.41% |
Dec 2025 | $15.87 | $18.70 | +19.00% |